Recording hERG potassium currents and assessing the effects of compounds using the whole-cell patch-clamp technique

Methods in Molecular Biology

Volumn 491, Issue , 2008, Pages 279-295

  Helliwell, Ray M ^a  

^a Millipore UK   (United Kingdom)

Author keywords

hERG; Patch clamp; Ion channels; Long QT; Safety pharmacology

Indexed keywords

EID: 60349085893     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-526-8_22     Document Type: Article

References (25)

1. Haverkamp, W., Breithardt, G., Camm, A.J., Janse, M.J., Rosen, M.R., Antzelevitch, C., Escande, D., Franz, M., Malik, M., Moss, A., and Shah, R. (2000) The potential for QT prolongation and proarrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res. 47, 219-233.
2. Gupta, A., Lawrence, A.T., Krishnan, K., Kavinsky, C.J., and Trohman, R.G. (2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am. Heart J. 153, 891-899.
3. Fermini, B. and Fossa, A.A. (2003) The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2, 439-447.
4. Shah, R.R. (2002) The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 54, 188-202.
5. Dorn, A., Hermann, F., Ebneth, A., Bothmann, H., Trube, G., Christensen, K., and Apfel, C. (2005) Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition. J. Biomol. Screen. 10, 339-347.
6. Guthrie, H., Livingston, F.S., Gubler, U., and Garippa, R. (2005) A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system. J. Biomol. Screen. 10, 832-840.
7. Diaz, G.J., Daniell, K., Leitza, S.T., Martin, R.L., Su, Z., McDermott, J.S., Cox, B.F., and Gintant, G.A. (2004) The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o. J. Pharmacol. Toxicol. Methods 50, 187-199.
8. Tang, W., Kang, J., Wu, X., Rampe, D., Wang, L., Shen, H., Li, Z., Dunnington, D., and Garyantes, T. (2001) Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen. 6, 325-331.
9. Kamiya, K., Niwa, R., Mitcheson, J.S., and Sanguinetti, M.C. (2006) Molecular determinants of HERG channel block. Mol. Pharmacol. 69, 1709-1716.
10. Rodriguez-Menchaca, A., Ferrer-Villada, T., Lara, J., Fernandez, D., Navarro-Polanco, R.A. and Sanchez-Chapula, J.A. (2006) Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J. Cardiovasc. Pharmacol. 47, 21-29.
11. Bottino, D., Penland, R.C., Stamps, A., Traebert, M., Dumotier, B., Georgiva, A., Helmlinger, G., and Lett, G.S. (2006) Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog. Biophys. Mol. Biol. 90, 414-443.
12. Crumb, W.J., Jr., Ekins, S., Sarazan, R.D., Wikel, J.H., Wrighton, S.A., Carlson, C., and Beasley, C.M., Jr. (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharmacol. Res. 23, 1133-1143.
13. Jamieson, C., Moir, E.M., Rankovic, Z., and Wishart, G. (2006) Medicinal chemistry of hERG optimizations: highlights and hang-ups. J. Med. Chem. 49, 5029-5046.
14. Wible, B.A., Hawryluk, P., Ficker, E., Kuryshev, Y.A., Kirsch, G., and Brown, A.M. (2005) HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136-145.
15. van der Heyden, M.A., Smits, M.E., and Vos, M.A. (2007) Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br. J. Pharmacol. 153, 406-409.
16. Hancox, J.C. and Curtis, M.J. (2006) Methods for screening drugs for their proarrhythmic liability: does the rabbit ventricular wedge hold the key? J. Pharmacol. Toxicol. Methods 54, 257-260.
17. Lawrence, C.L., Pollard, C.E., Hammond, T.G., and Valentin, J.P. (2005) Nonclinical proarrhythmia models: predicting Torsades de Pointes. J. Pharmacol. Toxicol. Methods 52, 46-59.
18. Shah, R.R. and Hondeghem, L.M. (2005) Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2, 758-772.
19. Valentin, J.P., Hoffmann, P., De Clerck, F., Hammond, T.G., and Hondeghem, L. (2004) Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods 49, 171-181.
20. Witchel, H.J., Milnes, J.T., Mitcheson, J.S., and Hancox, J.C. (2002) Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J. Pharmacol. Toxicol. Methods 48, 65-80.
21. Rudy, B. and Iversen, L.E. (eds.) (1992) Ion channels methods in enzymology 207. Academic, London.
22. Molleman, A. (2003) Patch clamping: an introductory guide to patch clamp electrophysiology. Wiley, Chichester.
23. Sakmann, B. and Neher E. (eds.) (1995) Single-channel recording. Plenum, New York.
24. Yao, J.A., Du, X., Lu, D., Baker, R.L., Daharsh, E., and Atterson, P. (2005) Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J. Pharmacol. Toxicol. Methods 52, 146-153.
25. Rampe, D., Roy, M.L., Dennis, A., and Brown, A.M. (1997) A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417, 28-32.